OPA1 mutation and late-onset cardiomyopathy: mitochondrial dysfunction and mtDNA instability.

L. Chen, Tingting Liu, Alice Tran, Xiyuan Lu, Alexey A. Tomilov, Vanessa Davies, Gino Cortopassi, Nipavan Chiamvimonvat, Donald M. Bers, Marcela Votruba, Anne A. Knowlton

Research output: Contribution to journalArticle

97 Scopus citations

Abstract

Mitochondrial fusion protein mutations are a cause of inherited neuropathies such as Charcot-Marie-Tooth disease and dominant optic atrophy. Previously we reported that the fusion protein optic atrophy 1 (OPA1) is decreased in heart failure. We investigated cardiac function, mitochondrial function, and mtDNA stability in a mouse model of the disease with OPA1 mutation. The homozygous mutation is embryonic lethal. Heterozygous OPA(+/-) mice exhibit reduced mtDNA copy number and decreased expression of nuclear antioxidant genes at 3 to 4 months. Although initial cardiac function was normal, at 12 months the OPA1(+/-) mouse hearts had decreased fractional shortening, cardiac output, and myocyte contraction. This coincided with the onset of blindness. In addition to small fragmented mitochondria, aged OPA1(+/-) mice had impaired cardiac mitochondrial function compared with wild-type littermates. OPA1 mutation leads to deficiency in antioxidant transcripts, increased reactive oxygen species, mitochondrial dysfunction, and late-onset cardiomyopathy.

Original languageEnglish (US)
JournalJournal of the American Heart Association
Volume1
Issue number5
DOIs
StatePublished - Oct 2012

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'OPA1 mutation and late-onset cardiomyopathy: mitochondrial dysfunction and mtDNA instability.'. Together they form a unique fingerprint.

  • Cite this